Skip to main content

Advertisement

SpringerLink
Log in

Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

Adjuvant chemotherapy with S-1 was proven to be effective in Japanese patients with advanced gastric cancer curatively resected with D2 lymph node dissection.

Materials and methods

We retrospectively evaluated the medical records of 305 patients with stage II, III or IV (M0) gastric cancer who had received adjuvant S-1 chemotherapy following curative gastrectomy with D2 lymph node dissection between October 2007 and December 2009. Adjuvant S-1 was administered at a dose of 40 mg/m2 twice daily for 4 weeks followed by 2 weeks of rest, every 6 weeks for eight cycles.

Results

Of the 305 patients, 248 (81.3 %) and 198 (64.9 %) completed four and eight cycles of adjuvant chemotherapy, respectively. The most common reasons for discontinuing treatment prior to the planned eight cycles were adverse events (n = 47, 15.4 %) and tumor recurrence (n = 28, 9.2 %). Sixty-five (21.3 %) patients required dose reduction due to adverse events. The most common grade 3/4 toxicities were neutropenia (n = 39, 12.8 %), diarrhea (n = 15, 4.9 %). Multivariate analysis showed that total gastrectomy [odds ratio (OR) 2.44; 95 % confidence interval (CI) 1.29–4.62, p = 0.006] was an independent risk factor for grade 3/4 hematologic toxicities, and age > 65 years (OR 2.60; 95 % CI 1.34–5.07, p = 0.005) was an independent risk factor for grade 3 non-hematologic toxicities.

Conclusions

Adjuvant chemotherapy with S-1 for 1 year is safe and feasible in Korean patients. Age > 65 years and total gastrectomy are independent risk factors for severe adverse events caused by adjuvant S-1 chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108

    Article  PubMed  Google Scholar 

  2. Jung KW, Park S, Kong HJ, Won YJ, Lee JY, Park EC, Lee JS (2011) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 43(1):1–11. doi:10.4143/crt.2011.43.1.1

    Article  PubMed  Google Scholar 

  3. Fuchs CS, Mayer RJ (1995) Gastric carcinoma. N Engl J Med 333(1):32–41. doi:10.1056/NEJM199507063330107

    Article  PubMed  CAS  Google Scholar 

  4. Earle CC, Maroun JA (1999) Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35(7):1059–1064

    Article  PubMed  CAS  Google Scholar 

  5. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V (2000) Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 11(7):837–843

    Article  PubMed  CAS  Google Scholar 

  6. Janunger KG, Hafstrom L, Glimelius B (2002) Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 168(11):597–608

    Article  PubMed  CAS  Google Scholar 

  7. Panzini I, Gianni L, Fattori PP, Tassinari D, Imola M, Fabbri P, Arcangeli V, Drudi G, Canuti D, Fochessati F, Ravaioli A (2002) Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88(1):21–27

    PubMed  CAS  Google Scholar 

  8. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725–730. doi:10.1056/NEJMoa010187

    Article  PubMed  CAS  Google Scholar 

  9. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20. doi:10.1056/NEJMoa055531

    Article  PubMed  CAS  Google Scholar 

  10. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820. doi:10.1056/NEJMoa072252

    Article  PubMed  CAS  Google Scholar 

  11. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Ji J, Yeh TS, Button P, Sirzen F, Noh SH (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. doi:10.1016/S0140-6736(11)61873-4

    PubMed  Google Scholar 

  12. Kang Y, Chang H, Zang D, Lee J, Kim T, Yang D, Jang S, Yook J, Oh S, Kim B (2008) Postoperative adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer: A randomized phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short- term doxifluridine (Mf) (AMC 0101) (NCT00296322). J Clin Oncol 26 (May 20 suppl; abstr LBA4511)

  13. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5):548–557

    Article  PubMed  CAS  Google Scholar 

  14. Pinkel D (1958) The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 18(7):853–856

    PubMed  CAS  Google Scholar 

  15. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181. doi:10.1016/S1053-4296(03)00031-6

    Article  PubMed  Google Scholar 

  16. Kinoshita T, Nashimoto A, Yamamura Y, Okamura T, Sasako M, Sakamoto J, Kojima H, Hiratsuka M, Arai K, Sairenji M, Fukushima N, Kimura H, Nakajima T (2004) Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer 7(2):104–109. doi:10.1007/s10120-004-0278-3

    Article  PubMed  CAS  Google Scholar 

  17. Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, Cho H, Tsuburaya A (2011) Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients. Gastric Cancer. doi:10.1007/s10120-011-0068-7

    Google Scholar 

  18. Iwasa S, Yamada Y, Fukagawa T, Eguchi Nakajima T, Kato K, Hamaguchi T, Morita S, Saka M, Katai H, Shimada Y (2011) Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification. Gastric Cancer 14(1):28–34. doi:10.1007/s10120-011-0003-y

    Article  PubMed  CAS  Google Scholar 

  19. Bozzetti F (1992) Total versus subtotal gastrectomy in cancer of the distal stomach: facts and fantasy. Eur J Surg Oncol 18(6):572–579

    PubMed  CAS  Google Scholar 

  20. Davies J, Johnston D, Sue-Ling H, Young S, May J, Griffith J, Miller G, Martin I (1998) Total or subtotal gastrectomy for gastric carcinoma? A study of quality of life. World J Surg 22(10):1048–1055

    Article  PubMed  CAS  Google Scholar 

  21. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M (2008) Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients. Cancer Chemother Pharmacol 61(2):335–343. doi:10.1007/s00280-007-0595-4

    Article  PubMed  CAS  Google Scholar 

  22. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Kawasaki T, Satomi T (2002) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother Pharmacol 50(1):25–32. doi:10.1007/s00280-002-0457-z

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

YKK has received a lecture honorarium from Taiho and Jeil pharmaceutical company.

Author information

Authors and Affiliations

  1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea

    Jae Ho Jeong, Min-Hee Ryu, Baek-Yeol Ryoo, Sung Sook Lee, Inkeun Park, Sang Hong Lee & Yoon-Koo Kang

  2. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea

    Kab Choong Kim, Jeong Hwan Yook, Sung Tae Oh & Byung Sik Kim

Authors
  1. Jae Ho Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min-Hee Ryu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Baek-Yeol Ryoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sung Sook Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Inkeun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sang Hong Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kab Choong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jeong Hwan Yook
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sung Tae Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Byung Sik Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoon-Koo Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoon-Koo Kang.

Additional information

Jae Ho Jeong, Min-Hee Ryu, and Baek-Yeol Ryoo contributed equally to the work as the first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jeong, J.H., Ryu, MH., Ryoo, BY. et al. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer. Cancer Chemother Pharmacol 70, 523–529 (2012). https://doi.org/10.1007/s00280-012-1935-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-012-1935-6

Keywords

Search

Navigation